drugset / Trial / NCT01860703
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
RandomizedCrossoverTriple-blindTreatment
Summary
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and supratherapeutic(50 mg/kg) oral doses of deferiprone in healthy volunteers as compared to placebo treatment.
Timeline
- Start
- 2012-11
- Primary completion
- 2012-12
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferiprone | Small molecule | 33 mg/kg | Oral |
| Subject | Deferiprone | Small molecule | 50 mg/kg | Oral |
| Subject | Moxifloxacin | Small molecule | 400 mg | — |
Indications
No indication recorded.